Search PubMed⌕ Search

Biomedical subjects

G Chouinard

Publications and source records attributed to G Chouinard.

At least 109 records · Page 6Linked to original sources
PubMed1985

Fluoxetine in the treatment of obsessive compulsive disorder.

In a 9-week open-label study, 7 outpatients with obsessive compulsive disorder were treated with fluoxetine, a selective inhibitor of neuronal reuptake of serotonin. A significant improvement was found in the symptomatology of patients as measured on the obsessive compulsive subscale of the Comprehensive Psychopathological Rating Scale (p less than 0.001) and the Clinical Global Impression of severity of illness (p less than 0.01). These findings support the hypothesis that serotoninergic antidepressants may be useful in the treatment of obsessive compulsive disorder.

Adult↗
PubMed1985

A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.

Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder. After a 1-week placebo washout, patients were randomly assigned to 5 weeks of treatment with fluoxetine or amitriptyline. Fluoxetine was found to have a therapeutic effect comparable to that of amitriptyline; however, the fluoxetine treatment group had a better Efficacy Index-Side Effects rating and a lower incidence of anticholinergic autonomic side effects. Four amitriptyline-treated patients had to discontinue the study because of serious side effects, while in the fluoxetine treatment group there were no terminations due to side effects. The amitriptyline-treated patients gained significantly more weight than the fluoxetine-treated patients.

Adult↗
PubMed1985

Schizophreniform psychosis associated with chronic industrial toluene exposure: case report.

Toluene is a solvent commonly used in the workplace and, in the last 25 years, it has gained notoriety as a substance of abuse. The central nervous system sequelae of both occupational and illicit exposure to toluene have been documented, and irreversible cerebellar changes have been described. Previous reports of psychosis associated with toluene have emphasized its reversibility. We report a case of an irreversible schizophreniform psychosis associated with 5 years of continuous occupational exposure to toluene.

Adult↗
PubMed1985

Plasma levels of neuroleptic in patients receiving depot fluphenazine.

Depot forms of fluphenazine are frequently used in the outpatient treatment of psychiatric patients. To gather relevant data on pharmacokinetic characteristics of depot fluphenazines, the authors measured plasma levels of neuroleptic activity in 76 clinic patients on stable dosage regimens of fluphenazine decanoate or fluphenazine enanthate. Dose and plasma neuroleptic activity level were highly correlated for both forms of depot fluphenazine. Furthermore, the slope of the regression of log dose to the log plasma neuroleptic activity was the same for both drug forms. However, doses of enanthate twice those of decanoate were associated with the same mean plasma level of neuroleptic activity. Finally, while blood levels of drug overlapped markedly in cohorts of patients receiving different doses of depot medication, the assumption of recent studies that, on the average, patients in such cohorts have different blood and tissue levels of drug was confirmed.

Delayed-Action Preparations↗
PubMed1984

Determination of plasma bupropion and its relationship to therapeutic effect.

An analytical method to determine the concentration of bupropion in human plasma has been developed using a deuterium-labeled analog as internal standard and selected ion monitoring applied to an extract of plasma samples taken as part of a clinical trial of this antidepressant. In all, 15 depressed outpatients were randomly assigned to bupropion in a double-blind study which included weekly evaluation of their clinical condition. A good correlation was found between the results obtained by this assay and by a radioimmunoassay technique currently in use. While no simple correlation between plasma concentration and therapeutic improvement was noted, the majority of subjects showed mild to marked amelioration of symptoms and those having mean concentrations above 35 ng ml-1 had significant improvement in their test scores. Interpretation of the mass spectra of both the labeled and unlabeled drug revealed an apparent violation of the 'even-electron rule'.

Amitriptyline↗
PubMed1984

An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients.

In a 6-week open-label study, ten newly admitted depressed patients were treated with tomoxetine , a selective inhibitor of noradrenaline reuptake. After 7 days of drug washout, patients were given an initial dose of 40 mg/day which was gradually increased to a maximum of 70 mg/day (median 50 mg/day). There was a statistically (P less than 0.001) and clinically significant improvement in the mean symptomatology of the patients measured on the Hamilton Depression Rating Scale. The drug had an early onset of action, a specific effect on mood, and no sedative properties.

Adult↗
PubMed1984

An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients.

Sixteen schizophrenic patients, who were newly admitted to hospital from the emergency room, underwent a 3-6-day washout before being treated for 4 weeks with BW234U, a dimethylpiperazinyl-propylcarbazole derivative. Eight patients showed moderate to marked improvement in schizophrenic symptoms and there was a statistically significant (P less than 0.001) reduction in the mean score for Clinical Global Impressions in all patients. Four patients did not complete the trial; two because of poor therapeutic effect, one because of a grand-mal seizure and one because of an episode of loss of consciousness of unknown origin. BW234U showed no evidence of neuroleptic plasma activity (as measured by radioreceptor assay), did not induce plasma prolactin elevation and did not appear to cause parkinsonism.

Acute Disease↗